David DeLucia
Mr. DeLucia has over 20 years of experience in the biopharmaceutical industry including early stage drug development, business development and management of strategic partnerships. Mr. DeLucia has been CEO ImmuRx, an immunotherapy based company co-founded with Dr. Noelle, and CEO of MIST Inc., a breast cancer imaging company. Prior to MIST, he led the development of a drug development technology platform at Millennium Pharmaceuticals which was spun out as part of a separate company in 2003. He has an M.S. from MIT and a B.A. from Dartmouth College.
Randolph Noelle
Dr. Noelle is co-founder and Vice Chair of ImmuNext, and Professor of Immunology at the Geisel School of Medicine at Dartmouth. His laboratory discovered the natural CD40 ligand, CD154, and the checkpoint regulator, VISTA. Dr. Noelle is in the top 5% of NIH funded scientists for total funding over his career and is a Fellow in the Academy of Medical Sciences.